Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.3 AUD | +2.77% | +3.59% | +29.35% |
03-25 | Miners, healthcare firms push Australia stocks higher | RE |
03-21 | Morgans Financial Downgrades Sigma Healthcare to Hold From Add; Price Target is AU$1.14 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- The company shows low valuation levels, with an enterprise value at 0.39 times its sales.
- The company has a low valuation given the cash flows generated by its activity.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- With an expected P/E ratio at 30.12 and 25.3 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+29.35% | 1.3B | B- | ||
+16.11% | 71.39B | C+ | ||
+1.98% | 25.1B | C+ | ||
-1.22% | 8.59B | C | ||
+7.95% | 8.19B | B | ||
-20.48% | 7.91B | B- | ||
+15.26% | 4.31B | B+ | ||
-1.24% | 3.93B | B- | ||
-3.02% | 3.86B | B | ||
+21.10% | 3.64B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SIG Stock
- Ratings Sigma Healthcare Limited